You are here:
Archived: glucosamine sulphate sodium chloride (Glusartel)
Advice
following a full submission
glucosamine sulphate (Glusartel®) is not recommended for use within NHS Scotland.
Indication under review: relief of symptoms in mild to moderate osteoarthritis (OA) of the knee.
In an active-comparator study, glucosamine sulphate 1,500mg once daily was superior to placebo in the treatment of symptoms associated with osteoarthritis of the knee.
The manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Drug Details
| Drug Name: | glucosamine sulphate sodium chloride (Glusartel) |
|---|---|
| SMC Drug ID: | 647/10 |
| Manufacturer: | HFA Healthcare Ltd |
| Indication: | for the treatment of OA of the knee. |
| BNF Category: | |
| Sub Category: | 10.1 Drugs used in rheumatic diseases and gout |
| Submission Type: | Full submission |
| Status: | Not Recommended |
| Date Advice Published: | 8 November 2010 |
Current Advice
| glucosamine sulphate (Glusartel) | Resubmission | 8 August 2011 |